ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL27759
CHEMBL27759
Compound Name ENTINOSTAT
ChEMBL Synonyms ENTINOSTAT | SNDX-275 | MS-275
Max Phase 3
Trade Names
Molecular Formula C21H20N4O3

Additional synonyms for CHEMBL27759 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2
Standard InChI InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15( ...
Download InChI
Standard InChI Key INVTYAOGFAGBOE-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • BindingDB Database
  • Clinical Candidates
  • Patent Bioactivity Data
  • PubChem BioAssays
  • Sanger Institute Genomics of Drug Sensitivity in Cancer
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names

Alternate Forms of Compound in ChEMBL


CHEMBL27759

Molecule Features

CHEMBL27759 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Unclassified Parenteral:Unclassified Topical:Unclassified Black Box:Unclassified Availability Type:Unclassified

Mechanism of Action

Mechanism of Action ChEMBL Target References
Histone deacetylase inhibitor Histone deacetylase PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Hodgkin DiseaseD006689EFO:0000183Hodgkins lymphoma2ClinicalTrials
MelanomaD008545EFO:0000756melanoma2ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000681renal cell carcinoma1ClinicalTrials
Triple Negative Breast NeoplasmsD064726EFO:0005537triple-negative breast cancer2ClinicalTrials
Breast Neoplasms, MaleD018567EFO:0006861male breast carcinoma2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000349clear cell renal carcinoma1ClinicalTrials
Carcinoma, Renal CellD002292EFO:0002890renal carcinoma1ClinicalTrials
LymphomaD008223EFO:0000574lymphoma2ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia1ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer1ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma1ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Myelodysplastic SyndromesD009190EFO:0000198myelodysplastic syndrome2ClinicalTrials

Clinical Data

ClinicalTrials.gov ENTINOSTAT
The Cochrane Collaboration ENTINOSTAT

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL27759. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL325 Histone deacetylase 1 Homo sapiens 1.000
CHEMBL1937 Histone deacetylase 2 Homo sapiens 1.000
CHEMBL1829 Histone deacetylase 3 Homo sapiens 1.000
CHEMBL340 Cytochrome P450 3A4 Homo sapiens 0.994
CHEMBL4001 Histone deacetylase 1 Mus musculus 0.357
CHEMBL3563 Cruzipain Trypanosoma cruzi 0.322
CHEMBL3397 Cytochrome P450 2C9 Homo sapiens 0.218



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL325 Histone deacetylase 1 Homo sapiens 1.000
CHEMBL1937 Histone deacetylase 2 Homo sapiens 1.000
CHEMBL1829 Histone deacetylase 3 Homo sapiens 1.000
CHEMBL2693 Cystinyl aminopeptidase Homo sapiens 0.999
CHEMBL4001 Histone deacetylase 1 Mus musculus 0.970
CHEMBL3192 Histone deacetylase 8 Homo sapiens 0.968
CHEMBL340 Cytochrome P450 3A4 Homo sapiens 0.732
CHEMBL2563 Histone deacetylase 5 Homo sapiens 0.459

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
376.4 376.1535 3.34 6 106.34 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 3 0 7 4 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
11.32 4.32 3.37 3.37 3 28 0.57

Structural Alerts

There are 4 structural alerts for CHEMBL27759. To view alerts please click here.

Compound Cross References

ChemSpider ChemSpider:INVTYAOGFAGBOE-UHFFFAOYSA-N
PubChem SID: 137275820 SID: 29217590 SID: 529250
Wikipedia Entinostat

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL27759



ACToR 209783-80-2
BindingDB 19410
Brenda 2694 24616 151866
ChEBI 132082
ChemicalBook CB2503893
DrugBank DB11841
eMolecules 31239709
EPA CompTox Dashboard DTXSID0041068
FDA SRS 1ZNY4FKK9H
Guide to Pharmacology 7007
IBM Patent System 66A84671A5C326931473815BA0C7FC35
LINCS LSM-4811
MolPort MolPort-005-942-713
Nikkaji J1.120.280B
PubChem 4261
PubChem: Drugs of the Future 12015232
PubChem: Thomson Pharma 14804341
Selleck MS-275
SureChEMBL SCHEMBL148309
ZINC ZINC000001488870

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/INVTYAOGFAGBOE-UHFFFAOYSA-N spacer
spacer